CRVO_OUT_1 [2025-03-27 12:18:00 -0400] 2369 Bytes | 721 tokens | Cum: 721 tkns (9.01% of 8k)
==========================================================================

We're scouting for winners today. Its 12:17:58 PM on Thu Mar 27, 2025 -0400 and I'm looking at CervoMed (CRVO) up to 9.28 from 7.71

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

Here's the first list of news for CervoMed:

C1 - Mar-25-25 08:00AM - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD )
C2 - Mar-22-25 11:00AM - Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings
C3 - Mar-22-25 11:00AM 02:55AM - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
C4 - Mar-19-25 04:27PM - Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
C5 - Mar-18-25 04:48AM - CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
C6 - Mar-17-25 08:00AM - CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
C7 - Mar-17-25 08:00AM 07:28AM - Why CervoMed Inc. (CRVO) Soared Last Week?
C8 - Mar-14-25 11:25AM - CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program

Prior AI Reports for CRVO:

1. 2025-03-21 – Score: 85 – Target: 21.6000 – Highs: 16.9400 / 14.9678 / 10.53
cervomed-incs-skyrocketing-sales-signal-bullish-market-trend
2. 2025-03-20 – Score: 65 – Target: 13.2500 – Highs: 12.2700 / 16.9400 / 14.97
cervomeds-strong-growth-tempered-by-market-skepticism

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on CervoMed (CRVO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CRVO_OUT_3 [2025-03-27 12:18:07 -0400] 1104 Bytes | 325 tokens | Cum: 1048 tkns (13.10% of 8k)
==========================================================================

Showing C1 (chunk 1 of 3): C1:
**CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD )**
Date: Mar-25-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/25/3048644/0/en/CervoMed-Announces-Oral-Presentation-at-19th-International-Conference-on-Alzheimer-s-and-Parkinson-s-Diseases-and-Related-Neurologic-Disorders-AP-PD.html

March 25, 2025 08:00 ET| Source:CervoMed Inc.CervoMed Inc.

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19thInternational Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Compa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_5 [2025-03-27 12:18:08 -0400] 998 Bytes | 283 tokens | Cum: 1401 tkns (17.51% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T12:26:54Z - CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital...
A2 - 2025-03-26T17:05:38Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Acrivon Therapeutics (NASDAQ:ACRV), A...
A3 - 2025-03-25T12:15:39Z - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's...
A4 - 2025-03-25T12:08:14Z - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's...
A5 - 2025-03-25T12:01:14Z - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CRVO_OUT_7 [2025-03-27 12:18:15 -0400] 1098 Bytes | 311 tokens | Cum: 1714 tkns (21.43% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital**Date: 2025-03-27Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/cervomed-nasdaqcrvo-given-buy-rating-at-d-boral-capital-2025-03-26/CervoMed (NASDAQ:CRVO - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital's target price points to a potential upside of 12.99% from the company's current price.

A number of other research analysts have also recently commented on the stock. Chardan Capital raised shares of CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 target price on the stock in a research report on Thursday, March 13th. Roth Capital upgrade

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_9 [2025-03-27 12:18:16 -0400] 1026 Bytes | 308 tokens | Cum: 2131 tkns (26.64% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-29T13:00:00Z - CervoMed to Present at the 8th International Lewy Body Dementia Conference
B2 - 2024-10-02T12:00:00Z - CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
B3 - 2024-06-11T12:00:00Z - CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
B4 - 2024-04-08T12:00:36Z - Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
B5 - 2024-04-01T12:00:00Z - CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
B6 - 2024-03-28T12:30:00Z - CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_11 [2025-03-27 12:18:23 -0400] 1098 Bytes | 315 tokens | Cum: 2448 tkns (30.60% of 8k)
==========================================================================

Showing B4 (chunk 1 of 2): B4:
**Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/04/38140071/disney-to-rally-around-10-here-are-10-top-analyst-forecasts-for-mondayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Canaccord Genuity boosted the price target for CervoMed Inc. (NASDAQ: CRVO) from $50 to $65. Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating. CervoMed shares fell 5.3% to close at $20.50 on Friday. See how other analysts view this stock.
Susquehanna increased the price target for Transocean Ltd. (NYSE: RIG) from $5.5 to $9. Susquehanna analyst Charles Minervino upgraded the stock from Neutral to Positive. Transocean shares fell 0.2% to close at

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_13 [2025-03-27 12:18:29 -0400] 594 Bytes | 171 tokens | Cum: 2732 tkns (34.15% of 8k)
==========================================================================

Showing B4 (chunk 2 of 2): $6.53 on Friday. See how other analysts view this stock.
Truist Securities raised Sealed Air Corporation (NYSE: SEE) price target from $39 to $44. Truist Securities analyst Michael Roxland upgraded the stock from Hold to Buy. Sealed Air shares fell 1.7% to close at $32.66 on Friday. See how other analysts view this stock.
Piper Sandler raised the price target for Perrigo Company plc ...

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_15 [2025-03-27 12:18:30 -0400] 1100 Bytes | 308 tokens | Cum: 3133 tkns (39.16% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S3 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_17 [2025-03-27 12:18:37 -0400] 1041 Bytes | 265 tokens | Cum: 3400 tkns (42.50% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_19 [2025-03-27 12:18:54 -0400] 4210 Bytes | 1216 tokens | Cum: 4728 tkns (59.10% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 1,027,694 | Perf Month: 300.80% | Option/Short: No / Yes | Sales Y/Y TTM: 142.42% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 4.61M | Perf Quarter: 301.71% | Short Float: 46.70% | ROE: -69.95% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.53 | Index: RUT | Short Ratio: 0.57 | ROI: -41.56% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 59.25 | Market Cap: 77.26M | Short Interest: 2.63M | Sales Surprise: 40.76% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.66 | Shs Outstand: 8.70M | Beta: 0.82 | EPS Surprise: -24.55% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 41.19% | Shs Float: 5.64M | Sales Q/Q: -13.19% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: 130.52% | Inst Own: 17.08% | Sales past 5Y: 7.26% | Earnings: Mar 17 BMO |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -15.20% | Insider Own: 35.20% | Employees: 15 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -23.20% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9737974.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -16290695.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.4014
Average Volume: 11853805.17
30-Day High: 14.29
30-Day Low: 2.12

[Detailed Financials: TTM 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: TTM 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,206,650.0

[Detailed Financials: FY 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: FY 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,206,650.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CRVO_OUT_21 [2025-03-27 12:18:59 -0400] 676 Bytes | 167 tokens | Cum: 5148 tkns (64.35% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CRVO_IN_23 [2025-03-27 12:19:00 -0400] 126 Bytes | 29 tokens | Cum: 5263 tkns (65.79% of 8k)
==========================================================================

====================================
[2025-03-27 09:19:00] # Analysis Completed
Elapsed Time: 62.43 seconds